Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2003
03/13/2003WO2004043335A2 Methods of treating infection by drug resistant bacteria
03/13/2003WO2003020962A2 Method of identifying glycosyl transferase binding compounds
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020930A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS
03/13/2003WO2003020889A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003WO2003020769A1 Pemphigus monoclonal antibody
03/13/2003WO2003020763A2 Soluble t cell receptor
03/13/2003WO2003020762A1 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
03/13/2003WO2003020755A1 Mutated env gene, mutated env glycoprotein and the use thereof
03/13/2003WO2003020754A2 Inhibition of replication factor c
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020746A1 Modified transferrin fusion proteins
03/13/2003WO2003020739A2 Novel lna compositions and uses thereof
03/13/2003WO2003020736A1 Crystaline clindamycin free base
03/13/2003WO2003020732A2 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors.
03/13/2003WO2003020730A1 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents
03/13/2003WO2003020729A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS
03/13/2003WO2003020728A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
03/13/2003WO2003020722A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
03/13/2003WO2003020721A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/13/2003WO2003020719A1 1,3-benzothiazinone derivatives and use thereof
03/13/2003WO2003020716A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003WO2003020709A1 1,2-oxazin-3-one derivatives as antibacterial agents
03/13/2003WO2003020705A1 Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors
03/13/2003WO2003020309A2 Compound
03/13/2003WO2003020304A2 Inflammation modulatory compound comprising an endomorphin
03/13/2003WO2003020302A1 Hepatitis b virus proliferation inhibitor
03/13/2003WO2003020298A1 Optimal compositions and methods thereof for treating hcv infections
03/13/2003WO2003020290A1 Therapeutic process for p. aeruginosa infections using macrolide antibiotics
03/13/2003WO2003020258A1 Anti-influenza drugs
03/13/2003WO2003020250A1 Plaster for the treatment of dysfunctions and disorders of nail growth
03/13/2003WO2003020249A1 Plaster for the treatment of dysfunctions and disorders of nails
03/13/2003WO2003020248A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
03/13/2003WO2003020222A2 PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020206A2 Use of atazanavir in hiv therapy
03/13/2003WO2003020108A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
03/13/2003WO2003020040A1 Oral vaccines
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003020029A1 Arylamines as inhibitors of chemokine binding to us28
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2003004472A8 Arylamines for the treatment of conditions associated with gsk-3
03/13/2003WO2003000225A3 Pharmaceutical formulation having a masked taste and method for the production thereof
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002085932A3 Constructs and methods for expression of recombinant hcv envelope proteins
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002069939A3 Taste masked pharmaceutical compositions
03/13/2003WO2002068654A3 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002065986A9 Transporters comprising spaced arginine moieties
03/13/2003WO2002060926A3 Hepatitis c tripeptide inhibitors
03/13/2003WO2002060379A3 Composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof
03/13/2003WO2002055104A3 Acne vaccine
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002048143A3 Antimicrobial 2-pyridones, their compositions and uses
03/13/2003WO2002046461A3 Method for identifying modulators of transcription
03/13/2003WO2002046459A3 Method for the determination of at least one functional polymorphism in the nucleotide sequence of a preselected candidate gene and its applications
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002045706A3 The use of polymers for inactivating pathogens
03/13/2003WO2002044364A3 Polypeptides involved in immune response
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002034293A3 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002022686A3 Defensin-antigen fusion proteins
03/13/2003WO2002012271A3 Treatment of microbial infections with bacterial proteins and peptides
03/13/2003WO2002000242A8 Human papilloma virus treatment
03/13/2003WO2002000168A3 Combination hiv therapy including camptothecin
03/13/2003WO2001096376A3 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
03/13/2003US20030050620 Combinatorial type controlled release drug delivery device
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050454 Oligonucleotide sfor use in the treatment of cancer and viral diseases
03/13/2003US20030050447 Polypeptide for use in the generation of vaccine against diphtheria toxin
03/13/2003US20030050439 Polypeptide for use in the treatment of tumors and warts
03/13/2003US20030050343 Novel potentiating compounds
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050296 Photodynamic porphyrin antimicrobial agents
03/13/2003US20030050279 Beta-glucans
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050261 Immunostimulatory nucleic acid molecules
03/13/2003US20030050254 Derivatives of erythromycin, their preparation process and their use as medicaments
03/13/2003US20030050253 The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections such as Herpes virus infections
03/13/2003US20030050248 Novel amino acid and peptide inhibitors of Staphylococcus virulence
03/13/2003US20030050247 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050229 Treatment with a 1' 2' and/or 3' nucleoside or a pharmaceutically acceptable salt or prodrug; nontoxic
03/13/2003US20030049844 Recombinant canine herpesviruses
03/13/2003US20030049830 Herpes virus complementing cell line
03/13/2003US20030049706 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of bacterial infections
03/13/2003US20030049648 37 staphylococcus aureus genes and polypeptides
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049604 Viral proteins for use in the treatment and prevention of infection and viral diseases
03/13/2003US20030049601 Detecting hepatitis in sample; obtain sample, incubate with binding agent, detect complex, presence of complex indicate hepatitis virus
03/13/2003US20030049331 Mixture of loop diuretics and lithium; contact lenses
03/13/2003US20030049281 Topical emulsion; quaternary ammonium salt emulsifier
03/13/2003US20030049279 Polysaccharide encapsualted antigen
1 ... 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 ... 1798